PSGL-1

PSGL-1 Molekülinformation

Englischer Name	P-selectin glycoprotein ligand-1	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	4	Target-Alias	P-selectin glycoprotein ligand 1，PSGL-1，SELPLG，Selectin P Ligand，Cutaneous Lymphocyte-Associated Associated Antigen，CD162 Antigen，CD162，PSGL1，CLA
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	P-selectin glycoprotein ligand-1
Target-Alias	P-selectin glycoprotein ligand 1，PSGL-1，SELPLG，Selectin P Ligand，Cutaneous Lymphocyte-Associated Associated Antigen，CD162 Antigen，CD162，PSGL1，CLA
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	4
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

PSGL-1 Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
His Tag (1)His Tag & Avi Tag (1)
Marker
Unconjugated (1)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
PS1-H52H9	Human	HEK293	Human PSGL-1 / CD162 Protein, His Tag				In den Warenkorb legen
PS1-H82E4	Human	HEK293	Biotinylated Human PSGL-1 / CD162 Protein, His,Avitag™				In den Warenkorb legen

Gesamtmenge2

PSGL-1 Molekülhintergrund

P-selectin glycoprotein ligand 1 (PSGL-1) is also known as Selectin P ligand (SELPLG), CD antigen CD162. PSGL-1 is disulfide-linked homodimer which is the high affinitycounter-receptor for P-selectin on expressed on activated endothelial cells and platelets. PSGL-1 / SELPLG interacts with P-, E- and L-selectins, through their lectin/EGF domains, is required for promoting recruitment and rolling of leukocytes. These interactions require sialyl Lewis X glycan modification but there is a differing dependence for tyrosine sulfations. Dimerization appears not to be required for P-selectin/SELP binding. PSGL-1 can interact with SNX20, MSN and SYK. PSGL-1 / SELPLG mediate the activation of SYK by SELPLG.

PSGL-1 Molekülalias

PSGL1,CD162,SELPLG,Selectin P ligand

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Cepeprubart	SelK-2	Phase 2 Clinical	Selexys	Asthma; Pulmonary Disease, Chronic Obstructive; Venous Thromboembolism	Details
Leiolizumab	AbGn 168H2; AbGn-268; AbGn-168H2; ALTB-268	Phase 2 Clinical	Altrubio Inc	Arthritis, Psoriatic; Colitis, Ulcerative	Details
Neihulizumab	AbGn-168; AbGn-168H; ALTB-168	Phase 1 Clinical	Altrubio Inc	Arthritis, Psoriatic; Colitis, Ulcerative; Graft vs Host Disease; Plaque psoriasis; Psoriasis	Details
SSGJ-617	SSGJ-617; SSGJ617; 61X; VTX-0811; 617	Phase 1 Clinical	Verseau Therapeutics Inc	Solid tumours	Details